HOTH

Handel nachbörslich: 1.02 0.01 +0.99%

Hoth Therapeutics Inc (HOTH)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Hoth Therapeutics Inc

(646)756-2997

590 MADISON AVENUE, NEW YORK, NY

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HOTH's Discussions on Twitter

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2019-10-15	Eingeleitet	The Benchmark Company	Speculative Buy

Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten

Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten

Hoth Therapeutics Inc [HOTH] Revenue clocked in at $0.00 million, down -25.69% YTD: What’s Next? - The DBT News

Balance Sheet Dive: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

C4 Therapeutics Inc (NASDAQ: CCCC) Up 14.34% This Year: What To Expect Next - Stocks Register

Hoth Therapeutics Inc (HOTH) Stock: Navigating a Year of Volatility - The InvestChronicle

Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data - MarketWatch

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ - StockTitan

Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal

Hoth Therapeutics Inc (HOTH) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Market Watch Highlights: Hoth Therapeutics Inc (HOTH) Ends on an Upturn Note at 1.12 - The Dwinnex

Hoth Therapeutics Inc [HOTH] Stock bought by Insider Knie Robb for $16750.0 - Knox Daily

AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback - ABBO News

Relay Therapeutics Shows Promising Results with RLY-2608 in Breast Cancer Study - BP Journal

Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance - BP Journal

Hoth Therapeutics Inc: Rising -68.55% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Are Hoth Therapeutics Inc’shares a good deal? - US Post News

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - MSN

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Zacks Investment Research

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Yahoo Finance

Hoth Therapeutics (NASDAQ: HOTH) Stock Skyrockets Following Approval of HT-001 Phase 2a Human Trials - ABBO News

Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Hoth Therapeutics ($HOTH) Advances to Phase 2a Trials with New Skin Toxicity Treatment - BP Journal

Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

Gold Moves Higher; Science Applications International Posts Upbeat EarningsChargePoint Hldgs (NYSE:CHPT) - Benzinga

Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient - MarketWatch

Dow Tumbles 1%; US Crude Oil Stocks FallSify Technologies (NASDAQ:SIFY) - Benzinga

HOTH’s valuation metrics: A comprehensive analysis - US Post News

Hoth reports rapid symptom relief in cancer treatment - Investing.com India

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - StockTitan

US Stocks Edge Higher; Jobless Claims Fall To 227,000 - Benzinga

Hoth reports rapid symptom relief in cancer treatment - Investing.com

Hoth Therapeutics jumps as skin toxicity drug shows promise in one patient - XM

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 - StockTitan

Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal

SPAR Group to Go Private in $2.50 Per Share Buyout by Highwire Capital - BP Journal

XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal

Applied DNA Sciences Inc. (NASDAQ: APDN): Expanding Horizons in DNA Technology and Clinical Testing - BP Journal

Hoth Therapeutics Inc (HOTH) rating initates by The Benchmark Company - Knox Daily

Hoth Therapeutics shares upgraded by EF Hutton on HT-001 potential - Investing.com

Hoth Therapeutics assumed with a Buy at EF Hutton - TipRanks

Titan Pharmaceuticals (TTNP) Announces Strategic Merger with KE Sdn. Bhd. - BP Journal

Hoth Therapeutics CEO purchases $16,750 in company stock - Investing.com

Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle

Hoth Therapeutics CEO purchases $16,750 in company stock By Investing.com - Investing.com Australia

ARCA Biopharma (ABIO) Announces Special Dividend Amid Merger with Oruka Therapeutics - BP Journal

Hoth Therapeutics Announces Positive Preclinical End Point Resul - GuruFocus.com

Hoth Therapeutics Announces Positive Final Results from 14-day P - GuruFocus.com

Hoth Therapeutics Inc (HOTH)’s Day in Review: Closing at 0.62, Up by 2.00 - The Dwinnex

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from HC Wainwright - Defense World

FDA Loophole Raises Concerns About Oncology Drug Approvals and More - OBR Oncology

Hoth and Aronnax partner for HT-KIT cancer therapy development - Yahoo Finance

Hoth and Aronnax partner for HT-KIT cancer therapy development - Pharmaceutical Technology

Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HOTH